Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Trisomy 13
Trisomy 13
Trisomy 13
Synonyms: Patau syndrome
Synonyms: Patau syndrome
Synonyms: Patau syndrome
Drug discovery
154
papers
On emerging therapies
Overview
Trisomy 13 (Patau Syndrome) is a severe chromosomal disorder caused by an extra chromosome 13, leading to multisystem congenital anomalies such as holoprosencephaly, cardiac defects, microphthalmia, cleft lip/palate, and polydactyly. Most cases arise spontaneously due to nondisjunction, with advanced maternal age increasing risk [1][12]. Prognosis is poor: ~50% die within the first week, and <10% survive beyond the first year [2][18]. Developmental delays, intellectual disability, and complex medical needs are universal in survivors [3][15].
Categories: rare abdominal surgical diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare renal diseases, rare transplant-related disorders
Research Papers
154 drug discovery papers about Trisomy 13. Recent publications:
154 drug discovery papers about Trisomy 13. Recent publications:
categories:
Small molecules
cell therapies
2025-10-07 | In vitro fertilization with preimplantation genetic testing compared with donor sperm and natural conception among male Robertsonian translocation carriers: a cost-effectiveness analysis.
To investigate the cost-effectiveness of reproductive strategies for male carriers of Robertsonian translocations. We designed a model to compare the outcomes and costs of three strategies: in vitro fertilization with preimplantation genetic testing for structural rearrangements (IVF PGT-SR), frozen donor sperm intrauterine insemination, and natural conception. The model was built using a Markov process to simulate one year of clinical care (up to 3 cycles of IVF, 6 intrauterine inseminations, or 12 attempts at natural conception), incorporating delays between cycles for adverse outcomes. Theoretical cohort of 2,751, an estimate of men aged 15-49 diagnosed with subfertility or nonsurgical sterility that are carriers of the most common Robertsonian translocation (13;14), within couples with fertility intention in one year. Reproductive strategy selection (IVF PGT-SR, donor sperm, natural conception). Outcomes included cost and quality-adjusted life years (QALYs) for the parents in addition to secondary outcomes of live births and decreased miscarriages, stillbirths, Trisomy 13 diagnoses, terminations, and neonatal deaths. A willingness-to-pay threshold was set at $100,000/QALY. Compared with natural conception, donor sperm and IVF PGT-SR increased overall live births and decreased miscarriages, stillbirths, Trisomy 13 diagnoses, terminations, and neonatal deaths, albeit at a higher cost. Using donor sperm vs. IVF PGT-SR resulted in cost savings with modest reductions in poor outcomes. Both alternative strategies to natural conception were cost-effective. Donor sperm and IVF PGT-SR yielded incremental cost-effectiveness ratios of $2,019 per QALY and $8,469 per QALY compared with natural conception, respectively. Utilizing IVF PGT-SR vs. donor sperm was not cost-effective with an incremental cost-effectiveness ratio of $722,138 per QALY. However, in sensitivity analysis, IVF PGT-SR became cost-effective over donor sperm when the utility of non-biological progeny was less than 0.99. For male rob(13;14) carriers, mother and offspring outcomes are improved with donor sperm and IVF PGT-SR. Utilizing donor sperm is a cost-effective conception strategy compared with both natural conception and IVF PGT-SR. For individuals strongly preferring biological progeny, IVF PGT-SR is cost-effective over donor sperm.
2021-07-14 | Impact of Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) on Birth Defects: A Systematic Review and Meta-Analysis
It is generally accepted that the incidence of birth defects in spontaneously conceived children ranges between 2.0-4.0%. However, several studies have shown that babies born after assisted reproductive technology (ART) procedures tend to present more congenital malformations than naturally conceived children, with 6.5% of the children born after intracytoplasmic sperm injection (ICSI) presenting birth defects. The use of high magnification sperm selection before ICSI was introduced in the early 2000s to allow the identification of spermatozoa with low risk of sperm DNA damage. Intracytoplasmic morphologically selected sperm injection (IMSI) is expected to change the incidence of congenital malformations, although data on the incidence of birth defects in children conceived after IMSI are still scarce.A systematic review based on searches performed in electronic databases (PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane Central Register of Controlled Trials) including articles published by February 2021 was conducted to identify trials comparing the neonatal outcomes of ICSI and IMSI. The outcome measured was the rate of birth defects in children born after ICSI or IMSI. Three trials were included as targets for data extraction and meta-analysis.Our meta-analysis included 3907 children conceived after IMSI (1280) or ICSI (2627). The incidence of birth defects was statistically different, with 2.5% (32/1280) in IMSI and 4.5% (119/2627) in ICSI (RR=0.59; 95% CI=0.40-0.87; p=0.007). The results demonstrated that IMSI decreased the incidence of structural defects compared to ICSI - 2.2% (18/830) vs. 3.8% (78/2049) - in a statistically significant manner (RR=0.58; 95%CI=0.35-0.96; p=0.04). No significant difference was observed in chromosomal abnormalities (Trisomy 13; 18; 21 and Triple X) between children conceived after IMSI (8/830) or ICSI (19/2049) (RR=1.07; 95%CI=0.47-2.43; p=0.87).IMSI seems to be an effective tool at reducing the incidence of structural defects compared to ICSI. However, IMSI does not change the incidence of chromosomal abnormalities.
2018-12-01 | Generation of a novel isogenic trisomy panel in human embryonic stem cells via microcell-mediated chromosome transfer
Aneuploidy is the gain or loss of a chromosome. Down syndrome or trisomy (Ts) 21 is the most frequent live-born aneuploidy syndrome in humans and extensively studied using model mice. However, there is no available model mouse for other congenital Ts syndromes, possibly because of the lethality of Ts in vivo, resulting in the lack of studies to identify the responsible gene(s) for aneuploid syndromes. Although induced pluripotent stem cells derived from patients are useful to analyse aneuploidy syndromes, there are concerns about differences in the genetic background for comparative studies and clonal variations. Therefore, a model cell line panel with the same genetic background has been strongly desired for sophisticated comparative analyses. In this study, we established isogenic human embryonic stem (hES) cells of Ts8, Ts13, and Ts18 in addition to previously established Ts21 by transferring each single chromosome into parental hES cells via microcell-mediated chromosome transfer. Genes on each trisomic chromosome were globally overexpressed in each established cell line, and all Ts cell lines differentiated into all three embryonic germ layers. This cell line panel is expected to be a useful resource to elucidate molecular and epigenetic mechanisms of genetic imbalance and determine how aneuploidy is involved in various abnormal phenotypes including tumourigenesis and impaired neurogenesis.
2017-11-07 | Prenatal and Postnatal Follow-up in Trisomies 13 and 18: A 20-Year Experience in a Tertiary Center
Objective Trisomies 13 and 18 are among the most common autosomal aneuploidies associated with high mortality rates. Conventional management strategies offer to limit interventional support; however, some of the recent studies suggest that intervention does make a difference in terms of survival. Study Design A retrospective cohort study was performed between January 1996 and January 2016, covering all cases with such trisomies. A total of 69 cases were reviewed for clinical aspects, outcome, and management strategies. Results In almost all pregnancies with follow-up, at least one indication present for invasive testing (54/55). Invasive testing was not performed in 18.5% of such cases. All parents opted for termination in cases with prenatal diagnosis. None of the liveborns had prenatal diagnoses, thus, neonatal resuscitation and intensive care unit admission were not withheld in such infants. Major intervention was done in only one patient with full trisomy 13. Median survival for infants with full trisomies 13 and 18 was 36 and 60 days, respectively. Almost half the patients died within 1 month. Conclusion To which extent the major interventions should be withheld is an issue of debate in managing such infants; however, current approaches are subject to change, given the technological advances.
1981-03-13 | Trisomic Hemopoietic Stem Cells of Fetal Origin Restore Hemopoiesis in Lethally Irradiated Mice
Autosomal trisomy in the mouse is invariably associated with fetal or early postnatal death. Hemopoietic stem cells from fetuses trisomic for chromosome 12 or 19 can be rescued by transplantation into lethally irradiated mice. These trisomic cells restore hemopoiesis, including lymphopoiesis, in the irradiated mice and establish a permanent and almost complete engraftment. There is no evidence that hemopoietic cells with trisomy 12 or 19 are cytogenetically unstable.
oligonucleotides
2022-05-16 | Clinical Validation and Diagnostic Utility of Optical Genome Mapping in Prenatal Diagnostic Testing
Abstract The standard-of-care (SOC) diagnostic prenatal testing includes a combination of cytogenetic methods such as karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarray (CMA) using either direct or cultured amniocytes or chorionic villi sampling (CVS). However, each technology has its limitations: karyotyping has a low resolution (>5Mb), FISH is targeted, and CMA does not detect balanced structural variants (SVs) or decipher complex rearrangements in the genome. These limitations necessitate the use of multiple tests, either simultaneously or sequentially to reach a genetic diagnosis. This long-standing prenatal testing workflow demonstrates the need for an alternative technology that can provide high-resolution results in a cost and time-effective manner. Optical genome mapping (OGM) is an emerging technology that has demonstrated its ability to detect all classes of SVs, including copy number variations (CNVs) and balanced abnormalities in a single assay, but has not been evaluated in the prenatal setting. This retrospective validation study analyzed 114 samples (including replicates), representing 94 unique and well-characterized samples that were received in our laboratory for traditional cytogenetic analysis with karyotyping, FISH, and/or CMA. Samples comprised 84 cultured amniocytes, and 10 phenotypically normal and cytogenetically negative controls. Six samples were run in triplicate to evaluate intra-run, inter-run, and inter-instrument reproducibility. Clinically relevant SVs and CNVs were reported using the Bionano Access software with standardized and built-in filtration criteria and phenotype-specific analysis. OGM was 100% concordant in identifying the 101 aberrations that included 29 interstitial/terminal deletions, 28 duplications, 26 aneuploidies, 6 absence of heterozygosity (AOH), 3 triploid genomes, 4 Isochromosomes, 1 translocation, and revealed the identity of 3 marker chromosomes, and 1 chromosome with additional material not determined by karyotyping. Additionally, OGM detected 64 additional clinically reportable SVs in 43 samples. OGM demonstrated high technical and analytical robustness and a limit of detection of 5% allele fraction for interstitial deletions and duplications, and 10% allele fraction for translocation and aneuploidy. This study demonstrates that OGM has the potential to identify unique genomic abnormalities such as CNVs, AOHs, and several classes of SVs including complex structural rearrangements. OGM has a standardized laboratory workflow and reporting solution that can be adopted in routine clinical laboratories and demonstrates the potential to replace the current SOC methods for prenatal diagnostic testing. We recommend its use as a first-tier genetic diagnostic test in a prenatal setting.
2018-06-01 | The dilemma of aneuploidy screening on low responders
Preimplantation genetic testing for aneuploidy (PGT-A) has been demonstrated to improve implantation and pregnancy rates and decrease miscarriage rates over standard morphology-based embryo selection. However, there are limited data on its efficacy in patients with diminished ovarian reserve or a poor response to stimulation who may have fewer embryos to select amongst.Early findings demonstrate that PGT-A reduces the miscarriage rate and decreases the time to delivery in poor responders. These studies highlight the importance of designing trials that compare outcomes over multiple cycles as the benefit of PGT-A in this patient population lies in eliminating the time lost to futile transfers of aneuploid embryos. Furthermore, recent studies have demonstrated that a catch-all category of 'poor responder' may need to be reevaluated as different subpopulations of patients with low response exhibit different clinical characteristics.More information is needed on characterizing the physiology of ovarian aging across multiple phenotypes of diminished ovarian reserve and establishing the predictive value of aneuploid results across multiple PGT-A platforms. However, initial data suggests benefit of PGT-A in poor responders.
2015-05-21 | BACs-on-Beads™ (BoBs™) assay for the genetic evaluation of prenatal samples and products of conception.
BACs-on-Beads™ (BoBs™) is a new emerging technology, a modification of comparative genomic hybridization that can be used to detect DNA copy number gains and losses. Here, we describe the application of two different types of BoBs™ assays: (1) Prenatal BoBs (CE-IVD) to detect the most frequent syndromes associated with chromosome microdeletions, as well as the trisomy 13, 18 and 21, and (2) KaryoLite BoBs (RUO) which can detect aneuploidy in all chromosomes by quantifying proximal and terminal regions of each chromosomal arm. The interpretation of the results by BoBsoft™ software is also described. Although BoBs™ may not have the breadth and scope to replace chromosomal microarrays (array comparative genomic hybridization and single nucleotide polymorphism array) in the prenatal setting, particularly when a fetal anomaly has been detected, it is a well suited alternative for FISH or QF-PCR because BoBs™ is comparable, if not superior in terms of cost, turnaround time (TAT) and throughput and accuracy. BoBs™ also has the ability to detect significant fetal mosaicism (≥30% with Prenatal BoBs and ≥50% with KaryoLite BoBs). However, perhaps the greatest strength of this new technology is the fact that unlike FISH or QF-PCR, it has the ability to detect common microdeletion syndromes or additional aneuploidies, both of which may be easily missed despite excellent prenatal sonography. Thus, when BoBs™ is applied in the correct clinical setting and run and analyzed in appropriate laboratories this technique can improve and augment best practices with a personalization of prenatal care.
2014-04-16 | Pre-implantation genetic screening using fluorescence in situ hybridization in couples of Indian ethnicity: Is there a scope?
There is a high incidence of numerical chromosomal aberration in couples with repeated in vitro fertilization (IVF) failure, advanced maternal age, repeated unexplained abortions, severe male factor infertility and unexplained infertility. Pre-implantation genetic screening (PGS), a variant of pre-implantation genetic diagnosis, screens numerical chromosomal aberrations in couples with normal karyotype, experiencing poor reproductive outcome. The present study includes the results of the initial pilot study on 9 couples who underwent 10 PGS cycles.The aim of the present study was to evaluate the beneficial effects of PGS in couples with poor reproductive outcome.Data of initial 9 couples who underwent 10 PGS for various indications was evaluated.Blastomere biopsy was performed on cleavage stage embryos and subjected to two round fluorescence in situ hybridization (FISH) testing for chromosomes 13, 18, 21, X and Y as a two-step procedure.Six of the 9 couples (10 PGS cycles) conceived, including a twin pregnancy in a couple with male factor infertility, singleton pregnancies in a couple with secondary infertility, in three couples with adverse obstetric outcome in earlier pregnancies and in one couple with repeated IVF failure.In the absence of availability of array-comparative genomic hybridization in diagnostic clinical scenario for PGS and promising results with FISH based PGS as evident from the current pilot study, it is imperative to offer the best available services in the present scenario for better pregnancy outcome for patients.
2008-09-01 | Array CGH for use in clinical preimplantation genetic screening
OBJECTIVE: Fluorescence in situ hybridisation (FISH) is the current gold standard for PGS with up to twelve chromosomes analyzed to detect chromosomal aneuploidy in embryos. Relatively few screened chromosomes may be sufficient to identify non-viable abnormalities in women >40 but younger women or those with repeated IVF failure may benefit from 24 chromosome screening. We describe preliminary results using Comparative Genomic Hybridisation microarrays (aCGH) to simultaneously screen multiple regions of each chromosome in single human lymphoblasts, blastomeres and embryos prior to clinical application. DESIGN: Prospective and blinded. MATERIALS AND METHODS: Single trisomy 13 lymphoblasts (Group 1), single blastomeres and corresponding embryos previously diagnosed by FISH from a single biopsied blastomere (Group 2) were subjected to whole genome amplification (WGA) using commercial kits. Amplified test and control DNA was labelled with Cy3/Cy5 in dye swap experiments with hybridisation against male and female control DNA (as positive controls) on an optimised BAC microarray (CytoChip v2) and analyzed using BlueFuse software (BlueGnome, Cambridge UK). RESULTS: In Group 1, trisomy 13 detection was unambiguous in both trisomic single cell samples. In Group 2 all embryos with evidence of successful WGA demonstrated successful aCGH. Embryo 1 diagnosed as monosomy 13, 18 & trisomy 22 by FISH was likely chromosomally mosaic since only trisomy 22 was confirmed by aCGH in the single blastomere along with multiple monosomies. The corresponding embryo was diagnosed as trisomy 12, monosomy 14 by aCGH. Embryo 2 diagnosed as monosomy 18 and trisomy 21 by FISH was confirmed in both the single cell and whole embryo by aCGH. Moreover, aCGH identified additional aneusomies (monosomy 5, 8, 10, 12, & trisomy 9 in both single cell and corresponding embryo). Embryo 3 diagnosed as normal by FISH was confirmed to be normal for 24 chromosomes after aCGH. CONCLUSIONS: The theoretical benefits of using a 24-chromosome screen are clear in terms of comprehensive chromosomal coverage to identify aneuploidies responsible for implantation failure, viable trisomies and miscarriage. Currently, using this approach, we could confidently detect chromosomal aneuploidies after blastocyst biopsy or for follow-up analysis and whole embryo aneuploidy risk assessment. With optimized cell lysis, whole genome amplification and hybridisation efficiency we could provide a 24-chromosome screen for single blastomeres in a feasible time frame for clinical PGS.
small molecules
2026-03-30 | Methyldopa as a novel therapeutic option for paroxysmal sympathetic hyperactivity in pediatric patients: A case report
Background Paroxysmal sympathetic hyperactivity (PSH) is a clinical syndrome characterized by intermittent episodes of excessive sympathetic and motor activity, including tachycardia, hypertension, hyperthermia, tachypnea, excessive diaphoresis, and abnormal posturing. Clonidine, an α2-adrenergic agonist, is used as a treatment for PSH, demonstrating efficacy across multiple studies. However, market withdrawal and the lack of a generic alternative in Japan have prompted the need for other therapeutic options. Case presentations Case 1 was 2-year-old boy with trisomy 13 complicated by holoprosencephaly, severe intellectual disability, and mixed quadriplegia. His PSH had been well-controlled with clonidine, which was successfully replaced with methyldopa after discontinuation of the former. Case 2 was a 1-year-old boy diagnosed with early infantile epileptic encephalopathy caused by a KCNQ2 mutation. PSH symptoms and elevated creatine kinase levels were alleviated with gabapentin and methyldopa. Discussion and conclusion We present the first two pediatric cases of PSH successfully managed with methyldopa, another α2-adrenergic agonist, as an alternative to clonidine. Methyldopa may serve as a promising alternative treatment for pediatric patients with PSH, particularly in settings where clonidine is unavailable. Further studies are required to evaluate the efficacy, safety, and long-term outcomes of methyldopa in this population.
2025-04-01 | Unresolved Grief Resurfacing: managing delayed perinatal grief after subsequent birth
Introduction Delayed perinatal grief occurs when the grieving process for a lost baby is reactivated after the birth of a healthy child. This case presents a 39-year-old mother who, after losing her first baby at 36 weeks due to Patau syndrome, experienced delayed grief following the birth of a full-term baby two years later. Despite receiving one psychological consultation at the time of the loss, the lack of follow-up contributed to the reactivation of her grief postpartum, presenting with sadness and anxiety. Objectives - To describe the process of delayed perinatal grief in a mother who lost a baby due to Patau syndrome. - To evaluate the psychological impact of the lack of follow-up after the loss on the subsequent development of reactivated grief. - To propose therapeutic interventions for the management of mothers experiencing delayed perinatal grief. Methods We present the case of a 39-year-old mother who lost a baby at 36 weeks of gestation due to Patau syndrome. Following the loss, she received a single psychological consultation with no further follow-up. Two years later, she gave birth to a healthy baby at 40 weeks, and six weeks after delivery, she was referred to psychiatry due to symptoms of profound sadness and anxiety, consistent with delayed perinatal grief. The patient was evaluated by the psychiatry team and began treatment with psychological intervention and pharmacological management when necessary. Results The psychiatric intervention led to a gradual improvement in symptoms of sadness and anxiety. The patient responded favorably to psychological treatment, incorporating cognitive-behavioral therapy techniques to manage grief. However, feelings of sadness persisted on dates related to the previous loss. Ongoing emotional support was crucial for the recovery process. Conclusions Delayed perinatal grief can reactivate after the birth of a new child, especially in cases where the original loss was not adequately followed up. Proper psychological support is essential to help mothers process their grief and prevent long-term emotional complications. Disclosure of Interest None Declared
2025-02-09 | Supportive effect of corticosteroid on bone marrow recovery in FLT3/ITD positive acute myeloid leukemia with trisomy 13.
Trisomy 13 is a rare chromosomal abnormality mainly observed in patients with FAB M0, and is associated with increased FLT3 expression, characterized by aggressive and inferior outcomes. Herein, we describe a case of FLT3/ITD-positive acute myeloid leukemia with trisomy 13, whose neutropenia and thrombocytopenia were improved by corticosteroids with a decrease in blasts in the peripheral blood without chemotherapy. Only short-term chemotherapy could be administered because of the patient's poor general condition. In contrast, repeated administration of methylprednisolone pulse therapy followed by high-dose prednisolone was required to control the interstitial pneumonitis. Although appropriate chemotherapy, such as oral administration of FLT inhibitors, could not be administered, a dramatic decrease in blasts and an increase in both neutrophils and platelets were observed. The addition of corticosteroids to chemotherapy is associated with a better clinical course in patients with hyperleukocytic and pediatric acute myeloid leukemia. In the present patient, the peripheral WBC count was not high, the steroids allowed for the recovery of normal hematopoiesis with diminishing blasts. Although stem cell transplantation is necessary to improve overall survival for aggressive acute myeloid leukemia, intensive chemotherapy cannot often be administered in frail older patients. Lower dose of steroids might be able to effectively control acute myeloid leukemia without serious adverse effects, resulting in a better clinical course in frail older patients with acute myeloid leukemia.
2024-01-23 | Clinical and neurological aspects of endocrine disorders in Down syndrome in children
BACKGROUND: Down syndrome is a common genetic pathology in which multiple defects are observed, including endocrine disorders of varying severity. Hypothyroidism occupies a leading position among all hormonal disorders in such children. However, the significance of hypofunction of the thyroid gland in the development and progression of cerebral dysfunction in children with trisomy 21 has not been sufficiently studied.
AIM: Assessment of the impact of endocrine pathology in children with Down syndrome on the state of neurological functions.
MATERIALS AND METHODS: We examined 50 children aged 3–5 years with complete trisomy of chromosome 21. At the same time, the number of boys was 13 (32%), girls — 27 (68%). Children of the main group had verified endocrine disorders associated with Down syndrome. Children in the control group had a confirmed diagnosis of Down syndrome, but did not have endocrine pathology, and their number was 10 people — 8 girls (80%) and 2 boys (20). Everyone underwent speech therapy and neuropsychological examination. Children of the main and control groups, in addition to standard biochemical and general blood tests, underwent a detailed laboratory study with determination of T3, T4, TSH levels. An advisory examination and dynamic observation by a speech therapist for 6 months. All children were assessed by a neurologist according to generally accepted methods.
RESULTS: Data have been obtained indicating a fairly widespread prevalence of thyroid dysfunction among patients with Down syndrome. However, clinical symptoms may not be specific due to their similarity to the phenotypic manifestations of a genetic disease. Thus, patients with clinically significant hypothyroidism had more severe cognitive impairment. There was a significantly lower level of psycho-speech development in 95.3±3.1% of cases (p 0.001) according to the results of comprehensive neuropsychological and speech therapy examinations. In the group of children with severe hypothyroidism, significantly more severe disorders of mental functions were encountered. At the same time, as thyroxine was prescribed in age-appropriate dosages for 3 months, the child’s condition improved, mnestic functions and voluntary attention improved in 60% of patients in the main group. In 70% of cases, there was an improvement in the evacuation function of the gastrointestinal tract, in 65% there was a normalization of the humidity and temperature of the skin.
CONCLUSION: Timely diagnosis of thyroid gland dysfunction is an important preventive measure for genetic abnormalities associated with multiple comorbid pathologies, such as trisomy 21, Down syndrome. Timely correction of existing disorders can improve the quality of life of such children and their relatives and can contribute to their adequate socialization and adaptation in modern society.
2021-12-31 | Keratoconus in a child with partial trisomy 13.
Background: Clinical studies suggest the importance of genetic components in the etiology of keratoconus. However, the contributing genes and variants remain elusive. We present a case of bilateral keratoconus in a child with partial trisomy 13, with a trisomic region spanning loci that have been associated with keratoconus.Materials and Methods: This is a single, retrospective case report of a child with a molecular diagnosis of partial trisomy 13, who was diagnosed with bilateral keratoconus for which at the age of 11 years, she underwent successive epithelium-off corneal cross-linking (CXL) procedures in both eyes, followed by temporary central tarsorrhaphy under general anesthesia.Results: Patient's molecular diagnosis was 70 Megabase trisomic region 13q14.11q34. Pre CXL pachymetry was 426 μm and 496 μm, maximum K values were 52.28 D and 55.45 D in right and left eyes, respectively; at last follow up (12 months post-op) these were 494 μm and 509 μm for pachymetry and maximum K values 50.50 D and 52.43 D in the right and left eyes, respectively. No signs of progression were detected.Conclusion: To the best of our knowledge, this is the first case report to document bilateral keratoconus in a child with partial trisomy 13, in whom successful epithelium-off CXL was achieved with general anesthesia. We emphasize the importance of screening, early diagnosis, and therapy of this treatable but rare cause of decreased vision in partial trisomy 13 patients.
gene therapies
2026-08-15 | PATAU SYNDROME IN A NEONATE: A CYTOGENETICALLY CONFIRMED CASE REPORT
Background: Patau syndrome is a severe chromosomal disorder caused by trisomy of chromosome 13 and is associated with a characteristic but variable combination of central nervous system, craniofacial, ocular, cardiac, renal, and limb abnormalities.A one-day-old female neonate born at 38 completed weeks to a 46-year-old mother Case Presentation: was evaluated for multiple congenital anomalies.Birth weight was 2.37 kg and Apgar scores were 6 and 7 at 1 and 5 minutes.Examination showed cleft lip and palate, low-set ears, left microphthalmia, and polydactyly of the right hand, left hand and left foot.Echocardiography demonstrated a moderate perimembranous ventricular septal defect with leftto-right shunting, a small secundum atrial septal defect, and a patent ductus arteriosus, with preserved biventricular function.Neurosonography was suggestive of semilobar holoprosencephaly.Renal ultrasonography showed bilateral enlarged echogenic kidneys with multiple cortical cysts, consistent with congenital cystic renal dysplasia.Ophthalmological examination confirmed left microphthalmia with iris and chorioretinal coloboma.Conventional GTGbanded chromosome analysis demonstrated 47,XX,+13[20], establishing full, free trisomy 13 without a detectable normal cell line in peripheral blood.The coexistence of semilobar holoprosencephaly, orofacial clefting, Conclusion: microphthalmia with coloboma, polydactyly, congenital heart disease, and cystic renal dysplasia is strongly suggestive of trisomy 13.Karyotyping confirms the diagnosis, defines the cytogenetic subtype, and provides the basis for accurate prognostic discussion and reproductive genetic counseling.
2026-02-28 | Prognostic Factors and Pregnancy Outcomes in Fetuses Diagnosed with Cystic Hygroma during the First Trimester
AbstractAim: To evaluate the genetic, sonographic, and clinical characteristics of fetuses diagnosed with cystic hygroma in the first trimester and to identify prognostic factors influencing pregnancy outcomes.Material and Methods: This retrospective study included pregnancies diagnosed with fetal cystic hygroma during the first trimester between January 2023 and June 2025 at a tertiary center. Demographic data, ultrasound findings, and results of invasive genetic testing were analyzed. Cases were compared according to the presence or absence of chromosomal abnormalities to assess clinical and perinatal outcomes.Results: A total of 84 patients prenatally diagnosed as cystic hygroma were analyzed. Chromosomal abnormalities were identified in 33 cases (39.3%), including trisomy 21 (n=13), monosomy X (n=10), trisomy 18 (n=6), trisomy 13 (n=3), and mosaicism (n=1). Major fetal anomalies were detected in 24 cases (28.6%), most commonly cardiac defects (n=19, 22.6%). Hydrops fetalis was present in 25 fetuses (29.8%). Compared with the normal karyotype group, patients with chromosomal abnormalities had higher maternal age (p=0.037), greater NT thickness (p=0.008), and increased rates of hydrops (p=0.003), intrauterine fetal death (p=0.03), and pregnancy termination (p
2026-02-20 | Peculiar Phenotype of Linear Prepubertal Hidradenitis Suppurativa Associated With Trisomy 13: Report of Two Clinical Cases.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that typically affects intertriginous areas and is rarely associated with chromosomal abnormalities. This report describes two pediatric cases of HS-like lesions overlying phylloid pigmentary mosaicism, both associated with mosaic trisomy 13. The first case involves a 5-year-old girl with developmental anomalies and comedonal lesions localized to areas of pigmentary mosaicism, confirmed by skin biopsy showing 30% aneuploid cells with full trisomy 13. The second case is a 15-month-old girl who developed follicular lesions years later overlying a hypopigmented mosaic patch; genetic analysis of skin tissue revealed 50% aneuploid cells with partial trisomy 13. These cases support an emerging link between mosaic trisomy 13 and follicular occlusion disorders, including HS. The involvement of chromosome 13 genes, such as GJB2 (connexin 26), may play a role in the pathogenesis.
2025-07-02 | Antenatal Diagnosis of Disorders of Sex Development Associated with Trisomy 13: A Case Report
Introduction: Disorders of sex development (DSD) are rare congenital conditions characterized by atypical genital, gonadal, or chromosomal sex, with an incidence of 1/10,000 births. Antenatal ultrasound can detect ambiguous genitalia, prompting specialized evaluation. Case Presentation: A 30-year-old primigravida’s fetus was diagnosed with ambiguous genitalia (micropenis, hypospadias) at 22 weeks’ gestation via ultrasound. Trophoblast biopsy confirmed trisomy 13, and postnatal examination revealed additional dysmorphic features. Results: Multidisciplinary antenatal management included specialized ultrasound and genetic counseling, with postnatal confirmation of DSD and trisomy 13. Conclusion: This case highlights the importance of antenatal ultrasound in detecting DSD, the association with trisomy 13, and the need for comprehensive genetic and multidisciplinary evaluation.
2025-04-01 | A Newborn with Dysmorphic Features with Congenital Abnormality of Skin (Answers)
Winner of the Clinical Quiz Dr. Deepa John Thomas Assistant Professor, Department of Pediatrics Mount Zion Medical College, Kerala.Question 1: Identify the scalp lesions Answer: The scalp lesion described is aplasia cutis congenita (ACC). Aplasia cutis congenita is a rare congenital skin defect with an incidence of approximately 1–3 out of 10,000 births.[1] It is characterized by a focal or extensive absence of the epidermis, dermis, and subcutaneous tissue.[2] Nearly 70% of ACC lesions are solitary on the scalp. Question 2: Name the classification proposed for this skin condition Answer: Frieden classification is used for ACC. Nine described varieties of ACC have been documented according to the Frieden classification. Group 1: Scalp ACC without multiple anomalies Group 2: Scalp ACC with limb abnormalities Group 3: Scalp ACC with epidermal and organoid nevi Group 4: ACC overlying congenital malformations Group 5: ACC with associated fetus papyraceous placental infarct Group 6: ACC with epidermolysis bullosa Group 7: ACC localized to extremities without blistering Group 8: ACC due to specific teratogens Group 9: ACC associated with malformation syndromes. This case falls under Group 9 – ACC associated with malformation syndromes. Question 3: Identify the syndrome based on Images 1 and 2 and the features described in textImage 1: Scalp and facial anomalies at birth. (a) Midline scalp defects (~2 cm) extending into both parietal regions. (b) Cleft lip/palate, microcephaly, and hypertelorismImage 2: Limb abnormalities in the newborn. (a) Clenched hands with overlapping fingers. (b) Bilateral foot deformitiesAnswer: Based on the clinical features described including multiple scalp defects (ACC), characteristic facial dysmorphism (cleft lip, cleft palate, microcephaly, and hypertelorism), distinctive hand positioning (clenched hands with outer fingers overlapping inner fingers), foot deformities, cardiac involvement evidenced by pan-systolic murmur, and severe growth restriction (weight 1.18 kg at 35 weeks), this constellation of findings is suggestive of Trisomy 13 (Patau syndrome). Patau syndrome is one of the most severe forms of autosomal trisomies, having a karyotype of trisomy 13, and an incidence is 1 in 20,000 live births.[3] Question 4: Name one autosomal dominant and one autosomal recessive condition associated with this skin disorder Answer: The autosomal dominant (AD) and autosomal recessive (AR) conditions associated with ACC[4] are shown in Table 1. The most well-documented AD/AR condition with ACC is Adams–Oliver syndrome, which uniquely can be inherited in both AD and AR patterns depending on the specific gene involved.Table 1: Autosomal dominant and recessive conditions associated with aplasia cutis congenitaDeclaration of patient consent The authors certify that the legal guardian has given consent for images and other clinical information to be reported in the journal. The guardian understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.Comments by Dr. Ankita Patel (Section Editor) We hope you all enjoyed this stimulating quiz. Although the pictures may have been obvious, it was heartening to see good responses to the theoretical questions too. These unusual cases serve as valuable learning opportunities, enriching our understanding and expanding our clinical expertise. It was so nice to see such zealous response from all the corners of the country, and most of the responses were correct.
other
2026-06-27 | Neuroinflammatory Vulnerability Windows in Trisomy 21: A Theoretical Framework for Extended-Interval IL-13/TSLP Biologic Intervention During Fetal Neurodevelopment
This preprint proposes a theoretical framework identifying three neuroinflammatory vulnerability windows in trisomy 21 (Down syndrome) fetal neurodevelopment — early neurogenesis (weeks 8–16), synaptic pruning (weeks 20–28), and myelination onset (weeks 28–36) — during which extended-interval IL-13/TSLP-targeting biologics could theoretically modulate neuroinflammatory burden across the entire critical developmental period within two to three injections. The June 2026 acquisition of Apogee Therapeutics by AbbVie, centred on zumilokibart (an IL-13-specific monoclonal antibody with 3–6 month dosing intervals), and the concurrent development of APG273 (IL-13/TSLP dual blockade) provide the pharmacological basis for this hypothesis. The paper includes: a mechanistic evidence chain table graded by evidence strength; a comparative inflammatory target analysis (interferon vs IL-13/TSLP vs JAK inhibition vs DYRK1A); translational precedents from prenatal enzyme replacement therapy, antisense oligonucleotides, and monoclonal antibody use in pregnancy; expanded FcRn placental pharmacokinetics; a staged preclinical research roadmap (iPSC organoids → Ts65Dn/Dp16 mouse models → placental perfusion → non-human primates); and explicit falsifiability criteria. A companion computational simulation (Python, open-source) models maternal-fetal pharmacokinetics via a PBPK model and downstream neuroinflammatory response via an ODE system, producing 7 publication-quality figures including a Monte Carlo sensitivity analysis (n=100) and composite Neurodevelopmental Index. Simulation code is available on GitHub and attached to this Zenodo record. This paper explicitly affirms the full dignity and personhood of individuals with trisomy 21. The framework targets neuroinflammatory burden as a secondary modifiable factor — analogous to folate supplementation — and is not oriented toward prevention of Down syndrome births. This is a theoretical hypothesis framework intended to stimulate preclinical investigation and is not a clinical recommendation. Submitted to Medical Hypotheses.
2025-02-12 | Treatment efficacy for infantile epileptic spasms syndrome in children with trisomy 21
Background Infantile Epileptic Spasms Syndrome (IESS) is the most common epilepsy syndrome in children with trisomy 21. First-line standard treatments for IESS include adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin. Among children with trisomy 21 and IESS, treatment with ACTH or oral corticosteroids may yield higher response rates compared with vigabatrin. However, supporting data are largely from single-center, retrospective cohort studies. Methods Leveraging the multi-center, prospective National Infantile Spasms Consortium (NISC) database, we evaluated the efficacy of first-line (standard) treatments for IESS in children with trisomy 21. We assessed clinical spasms remission at two weeks, clinical spasms remission at three months, and improvement of EEG (resolution of hypsarrhythmia) three months after initiation of treatment. Results Thirty four of 644 (5.3%) children with IESS were diagnosed with trisomy 21. In all children with trisomy 21, epileptic spasms was their presenting seizure type. Twenty of 34 (59%) children were initially treated with ACTH, nine (26%) with oral corticosteroids, and five (15%) with vigabatrin. Baseline demographics did not vary among treatment groups. The overall clinical remission rate after two weeks of treatment was 53% including 13 of 20 (65%) receiving ACTH, three of nine (33%) receiving oral corticosteroids, and two of five (40%) receiving vigabatrin ( p = 0.24). The continued clinical response rate at three months was 32% including 8 of 20 (40%) receiving ACTH, two of nine (22%) receiving oral corticosteroids, and one of five (20%) receiving vigabatrin. Thirty of the 34 (88%) children presented with hypsarrhythmia (88%). EEG improvement at three months was better for children treated with ACTH (74%) or oral corticosteroids (83%) than vigabatrin (20%; p = 0.048). Adjustment for time from epileptic spasms onset to treatment did not alter results. Conclusions In our cohort, epileptic spasms were the first presenting seizure type in all children with trisomy 21. Among first-line standard treatment options, ACTH may have superior efficacy for clinical and electrographic outcomes for IESS in children with trisomy 21.
2022-07-11 | Severe recalcitrant hidradenitis suppurativa in a 2-year-old boy with partial trisomy 13.
We report the case of a 2-year-old boy with mosaic trisomy 13 and immunodeficiency who developed severe hidradenitis suppurativa beginning at the age of 18 months. Unresponsive to standard therapies, he exhibited a partial response to immunoglobulin replacement therapy.
2020-10-09 | Characteristics of the Central Nervous System Malformations Presented in Trisomy 13: A single-center Experience in Recognizing the Phenotype and Genotype
BACKGROUND: Patients who are diagnosed with trisomy 13 (Patau syndrome) are known to have a poor prognosis. It has been hypothesized that such poor outcomes are suspected to be attributed to their central nervous system (CNS)-malformations and cardiac-malformations. This study was conducted at Division of Neuropediatric, Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran – Dr. Hasan Sadikin Hospital, Bandung (2012–2018).
AIM: This study aimed to describe clinical characteristics and karyotype findings in patients who were diagnosed with Patau syndrome and treated at our center. Since Indonesia is still categorized as a lower middle-income country with limited resources, we expected that this study would provide a clinical reference on how a congenital disease with chromosomal abnormalities is confirmed.
CASE PRESENTATION: Our cases indicate that CNS malformations are likely to be the cause of indirect mortality of patients’ early period of life. The median survival in our study is 7 days, while the longest survival is 30 days. The major cause of death is apnea, which found in 4 of 5 diagnosed infants. One patient died of severe infection. In most cases, where CNS malformations were observed microcephaly with sloping forehead, Dandy–Walker syndrome, lobar or alobar holoprosencephaly and ventriculomegaly were identified, as well as neural tube defects (NTDs) were identified, such as spina bifida and meningoencephalocele. CNS malformations, such as holoprosencephaly, may be associated with episodes characterized by temporary cessation of spontaneous breathing (apnea) as direct cause of mortality.
CONCLUSION: We conclude that early treatment in Patau syndrome patient in our center should be focused on more life-threatening problem caused by CNS malformations than NTDs defects, such defects could be managed electively.
2017-05-07 | Acne conglobata in a long‐term survivor with trisomy 13, accompanied by selective IgM deficiency
Trisomy 13 (T13) is a congenital chromosomal disorder that is usually fatal within 2 years of birth, and only a few patients have been reported to reach adolescence. Here, we report a male long‐term survivor of T13, currently 15 years of age, with a several‐year history of extensive acne conglobata (AC) with abscesses on the face and neck. Methicillin‐resistant Staphylococcus aureus was consistently isolated from the pustular lesions. Serum IgM levels were extremely low at 10 mg/dl. There were no abnormalities in neutrophil and total B cell number, or in serum IgA and IgG levels. Increased CD8+ T cell counts and inversion of the CD4/CD8 ratio were observed repeatedly. The patient's clinical features and laboratory data support a diagnosis of selective IgM deficiency (SIgMD) with concurrent AC. Immunoglobulin replacement therapy elevated serum IgM levels to the normal range and reduced the severity of AC. We suggest that T13 may represent a syndromic disorder associated with multiple organ malformation and a risk of developing immunodeficiency involving SIgMD. Because pediatric SIgMD is rare and an immunological abnormality in T13 patients has not previously been reported, we describe the patient's clinical course.
cell therapies
2025-10-07 | In vitro fertilization with preimplantation genetic testing compared with donor sperm and natural conception among male Robertsonian translocation carriers: a cost-effectiveness analysis.
To investigate the cost-effectiveness of reproductive strategies for male carriers of Robertsonian translocations. We designed a model to compare the outcomes and costs of three strategies: in vitro fertilization with preimplantation genetic testing for structural rearrangements (IVF PGT-SR), frozen donor sperm intrauterine insemination, and natural conception. The model was built using a Markov process to simulate one year of clinical care (up to 3 cycles of IVF, 6 intrauterine inseminations, or 12 attempts at natural conception), incorporating delays between cycles for adverse outcomes. Theoretical cohort of 2,751, an estimate of men aged 15-49 diagnosed with subfertility or nonsurgical sterility that are carriers of the most common Robertsonian translocation (13;14), within couples with fertility intention in one year. Reproductive strategy selection (IVF PGT-SR, donor sperm, natural conception). Outcomes included cost and quality-adjusted life years (QALYs) for the parents in addition to secondary outcomes of live births and decreased miscarriages, stillbirths, Trisomy 13 diagnoses, terminations, and neonatal deaths. A willingness-to-pay threshold was set at $100,000/QALY. Compared with natural conception, donor sperm and IVF PGT-SR increased overall live births and decreased miscarriages, stillbirths, Trisomy 13 diagnoses, terminations, and neonatal deaths, albeit at a higher cost. Using donor sperm vs. IVF PGT-SR resulted in cost savings with modest reductions in poor outcomes. Both alternative strategies to natural conception were cost-effective. Donor sperm and IVF PGT-SR yielded incremental cost-effectiveness ratios of $2,019 per QALY and $8,469 per QALY compared with natural conception, respectively. Utilizing IVF PGT-SR vs. donor sperm was not cost-effective with an incremental cost-effectiveness ratio of $722,138 per QALY. However, in sensitivity analysis, IVF PGT-SR became cost-effective over donor sperm when the utility of non-biological progeny was less than 0.99. For male rob(13;14) carriers, mother and offspring outcomes are improved with donor sperm and IVF PGT-SR. Utilizing donor sperm is a cost-effective conception strategy compared with both natural conception and IVF PGT-SR. For individuals strongly preferring biological progeny, IVF PGT-SR is cost-effective over donor sperm.
2021-07-14 | Impact of Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) on Birth Defects: A Systematic Review and Meta-Analysis
It is generally accepted that the incidence of birth defects in spontaneously conceived children ranges between 2.0-4.0%. However, several studies have shown that babies born after assisted reproductive technology (ART) procedures tend to present more congenital malformations than naturally conceived children, with 6.5% of the children born after intracytoplasmic sperm injection (ICSI) presenting birth defects. The use of high magnification sperm selection before ICSI was introduced in the early 2000s to allow the identification of spermatozoa with low risk of sperm DNA damage. Intracytoplasmic morphologically selected sperm injection (IMSI) is expected to change the incidence of congenital malformations, although data on the incidence of birth defects in children conceived after IMSI are still scarce.A systematic review based on searches performed in electronic databases (PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane Central Register of Controlled Trials) including articles published by February 2021 was conducted to identify trials comparing the neonatal outcomes of ICSI and IMSI. The outcome measured was the rate of birth defects in children born after ICSI or IMSI. Three trials were included as targets for data extraction and meta-analysis.Our meta-analysis included 3907 children conceived after IMSI (1280) or ICSI (2627). The incidence of birth defects was statistically different, with 2.5% (32/1280) in IMSI and 4.5% (119/2627) in ICSI (RR=0.59; 95% CI=0.40-0.87; p=0.007). The results demonstrated that IMSI decreased the incidence of structural defects compared to ICSI - 2.2% (18/830) vs. 3.8% (78/2049) - in a statistically significant manner (RR=0.58; 95%CI=0.35-0.96; p=0.04). No significant difference was observed in chromosomal abnormalities (Trisomy 13; 18; 21 and Triple X) between children conceived after IMSI (8/830) or ICSI (19/2049) (RR=1.07; 95%CI=0.47-2.43; p=0.87).IMSI seems to be an effective tool at reducing the incidence of structural defects compared to ICSI. However, IMSI does not change the incidence of chromosomal abnormalities.
2018-12-01 | Generation of a novel isogenic trisomy panel in human embryonic stem cells via microcell-mediated chromosome transfer
Aneuploidy is the gain or loss of a chromosome. Down syndrome or trisomy (Ts) 21 is the most frequent live-born aneuploidy syndrome in humans and extensively studied using model mice. However, there is no available model mouse for other congenital Ts syndromes, possibly because of the lethality of Ts in vivo, resulting in the lack of studies to identify the responsible gene(s) for aneuploid syndromes. Although induced pluripotent stem cells derived from patients are useful to analyse aneuploidy syndromes, there are concerns about differences in the genetic background for comparative studies and clonal variations. Therefore, a model cell line panel with the same genetic background has been strongly desired for sophisticated comparative analyses. In this study, we established isogenic human embryonic stem (hES) cells of Ts8, Ts13, and Ts18 in addition to previously established Ts21 by transferring each single chromosome into parental hES cells via microcell-mediated chromosome transfer. Genes on each trisomic chromosome were globally overexpressed in each established cell line, and all Ts cell lines differentiated into all three embryonic germ layers. This cell line panel is expected to be a useful resource to elucidate molecular and epigenetic mechanisms of genetic imbalance and determine how aneuploidy is involved in various abnormal phenotypes including tumourigenesis and impaired neurogenesis.
2017-11-07 | Prenatal and Postnatal Follow-up in Trisomies 13 and 18: A 20-Year Experience in a Tertiary Center
Objective Trisomies 13 and 18 are among the most common autosomal aneuploidies associated with high mortality rates. Conventional management strategies offer to limit interventional support; however, some of the recent studies suggest that intervention does make a difference in terms of survival. Study Design A retrospective cohort study was performed between January 1996 and January 2016, covering all cases with such trisomies. A total of 69 cases were reviewed for clinical aspects, outcome, and management strategies. Results In almost all pregnancies with follow-up, at least one indication present for invasive testing (54/55). Invasive testing was not performed in 18.5% of such cases. All parents opted for termination in cases with prenatal diagnosis. None of the liveborns had prenatal diagnoses, thus, neonatal resuscitation and intensive care unit admission were not withheld in such infants. Major intervention was done in only one patient with full trisomy 13. Median survival for infants with full trisomies 13 and 18 was 36 and 60 days, respectively. Almost half the patients died within 1 month. Conclusion To which extent the major interventions should be withheld is an issue of debate in managing such infants; however, current approaches are subject to change, given the technological advances.
1981-03-13 | Trisomic Hemopoietic Stem Cells of Fetal Origin Restore Hemopoiesis in Lethally Irradiated Mice
Autosomal trisomy in the mouse is invariably associated with fetal or early postnatal death. Hemopoietic stem cells from fetuses trisomic for chromosome 12 or 19 can be rescued by transplantation into lethally irradiated mice. These trisomic cells restore hemopoiesis, including lymphopoiesis, in the irradiated mice and establish a permanent and almost complete engraftment. There is no evidence that hemopoietic cells with trisomy 12 or 19 are cytogenetically unstable.
oligonucleotides
2022-05-16 | Clinical Validation and Diagnostic Utility of Optical Genome Mapping in Prenatal Diagnostic Testing
Abstract The standard-of-care (SOC) diagnostic prenatal testing includes a combination of cytogenetic methods such as karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarray (CMA) using either direct or cultured amniocytes or chorionic villi sampling (CVS). However, each technology has its limitations: karyotyping has a low resolution (>5Mb), FISH is targeted, and CMA does not detect balanced structural variants (SVs) or decipher complex rearrangements in the genome. These limitations necessitate the use of multiple tests, either simultaneously or sequentially to reach a genetic diagnosis. This long-standing prenatal testing workflow demonstrates the need for an alternative technology that can provide high-resolution results in a cost and time-effective manner. Optical genome mapping (OGM) is an emerging technology that has demonstrated its ability to detect all classes of SVs, including copy number variations (CNVs) and balanced abnormalities in a single assay, but has not been evaluated in the prenatal setting. This retrospective validation study analyzed 114 samples (including replicates), representing 94 unique and well-characterized samples that were received in our laboratory for traditional cytogenetic analysis with karyotyping, FISH, and/or CMA. Samples comprised 84 cultured amniocytes, and 10 phenotypically normal and cytogenetically negative controls. Six samples were run in triplicate to evaluate intra-run, inter-run, and inter-instrument reproducibility. Clinically relevant SVs and CNVs were reported using the Bionano Access software with standardized and built-in filtration criteria and phenotype-specific analysis. OGM was 100% concordant in identifying the 101 aberrations that included 29 interstitial/terminal deletions, 28 duplications, 26 aneuploidies, 6 absence of heterozygosity (AOH), 3 triploid genomes, 4 Isochromosomes, 1 translocation, and revealed the identity of 3 marker chromosomes, and 1 chromosome with additional material not determined by karyotyping. Additionally, OGM detected 64 additional clinically reportable SVs in 43 samples. OGM demonstrated high technical and analytical robustness and a limit of detection of 5% allele fraction for interstitial deletions and duplications, and 10% allele fraction for translocation and aneuploidy. This study demonstrates that OGM has the potential to identify unique genomic abnormalities such as CNVs, AOHs, and several classes of SVs including complex structural rearrangements. OGM has a standardized laboratory workflow and reporting solution that can be adopted in routine clinical laboratories and demonstrates the potential to replace the current SOC methods for prenatal diagnostic testing. We recommend its use as a first-tier genetic diagnostic test in a prenatal setting.
2018-06-01 | The dilemma of aneuploidy screening on low responders
Preimplantation genetic testing for aneuploidy (PGT-A) has been demonstrated to improve implantation and pregnancy rates and decrease miscarriage rates over standard morphology-based embryo selection. However, there are limited data on its efficacy in patients with diminished ovarian reserve or a poor response to stimulation who may have fewer embryos to select amongst.Early findings demonstrate that PGT-A reduces the miscarriage rate and decreases the time to delivery in poor responders. These studies highlight the importance of designing trials that compare outcomes over multiple cycles as the benefit of PGT-A in this patient population lies in eliminating the time lost to futile transfers of aneuploid embryos. Furthermore, recent studies have demonstrated that a catch-all category of 'poor responder' may need to be reevaluated as different subpopulations of patients with low response exhibit different clinical characteristics.More information is needed on characterizing the physiology of ovarian aging across multiple phenotypes of diminished ovarian reserve and establishing the predictive value of aneuploid results across multiple PGT-A platforms. However, initial data suggests benefit of PGT-A in poor responders.
2015-05-21 | BACs-on-Beads™ (BoBs™) assay for the genetic evaluation of prenatal samples and products of conception.
BACs-on-Beads™ (BoBs™) is a new emerging technology, a modification of comparative genomic hybridization that can be used to detect DNA copy number gains and losses. Here, we describe the application of two different types of BoBs™ assays: (1) Prenatal BoBs (CE-IVD) to detect the most frequent syndromes associated with chromosome microdeletions, as well as the trisomy 13, 18 and 21, and (2) KaryoLite BoBs (RUO) which can detect aneuploidy in all chromosomes by quantifying proximal and terminal regions of each chromosomal arm. The interpretation of the results by BoBsoft™ software is also described. Although BoBs™ may not have the breadth and scope to replace chromosomal microarrays (array comparative genomic hybridization and single nucleotide polymorphism array) in the prenatal setting, particularly when a fetal anomaly has been detected, it is a well suited alternative for FISH or QF-PCR because BoBs™ is comparable, if not superior in terms of cost, turnaround time (TAT) and throughput and accuracy. BoBs™ also has the ability to detect significant fetal mosaicism (≥30% with Prenatal BoBs and ≥50% with KaryoLite BoBs). However, perhaps the greatest strength of this new technology is the fact that unlike FISH or QF-PCR, it has the ability to detect common microdeletion syndromes or additional aneuploidies, both of which may be easily missed despite excellent prenatal sonography. Thus, when BoBs™ is applied in the correct clinical setting and run and analyzed in appropriate laboratories this technique can improve and augment best practices with a personalization of prenatal care.
2014-04-16 | Pre-implantation genetic screening using fluorescence in situ hybridization in couples of Indian ethnicity: Is there a scope?
There is a high incidence of numerical chromosomal aberration in couples with repeated in vitro fertilization (IVF) failure, advanced maternal age, repeated unexplained abortions, severe male factor infertility and unexplained infertility. Pre-implantation genetic screening (PGS), a variant of pre-implantation genetic diagnosis, screens numerical chromosomal aberrations in couples with normal karyotype, experiencing poor reproductive outcome. The present study includes the results of the initial pilot study on 9 couples who underwent 10 PGS cycles.The aim of the present study was to evaluate the beneficial effects of PGS in couples with poor reproductive outcome.Data of initial 9 couples who underwent 10 PGS for various indications was evaluated.Blastomere biopsy was performed on cleavage stage embryos and subjected to two round fluorescence in situ hybridization (FISH) testing for chromosomes 13, 18, 21, X and Y as a two-step procedure.Six of the 9 couples (10 PGS cycles) conceived, including a twin pregnancy in a couple with male factor infertility, singleton pregnancies in a couple with secondary infertility, in three couples with adverse obstetric outcome in earlier pregnancies and in one couple with repeated IVF failure.In the absence of availability of array-comparative genomic hybridization in diagnostic clinical scenario for PGS and promising results with FISH based PGS as evident from the current pilot study, it is imperative to offer the best available services in the present scenario for better pregnancy outcome for patients.
2008-09-01 | Array CGH for use in clinical preimplantation genetic screening
OBJECTIVE: Fluorescence in situ hybridisation (FISH) is the current gold standard for PGS with up to twelve chromosomes analyzed to detect chromosomal aneuploidy in embryos. Relatively few screened chromosomes may be sufficient to identify non-viable abnormalities in women >40 but younger women or those with repeated IVF failure may benefit from 24 chromosome screening. We describe preliminary results using Comparative Genomic Hybridisation microarrays (aCGH) to simultaneously screen multiple regions of each chromosome in single human lymphoblasts, blastomeres and embryos prior to clinical application. DESIGN: Prospective and blinded. MATERIALS AND METHODS: Single trisomy 13 lymphoblasts (Group 1), single blastomeres and corresponding embryos previously diagnosed by FISH from a single biopsied blastomere (Group 2) were subjected to whole genome amplification (WGA) using commercial kits. Amplified test and control DNA was labelled with Cy3/Cy5 in dye swap experiments with hybridisation against male and female control DNA (as positive controls) on an optimised BAC microarray (CytoChip v2) and analyzed using BlueFuse software (BlueGnome, Cambridge UK). RESULTS: In Group 1, trisomy 13 detection was unambiguous in both trisomic single cell samples. In Group 2 all embryos with evidence of successful WGA demonstrated successful aCGH. Embryo 1 diagnosed as monosomy 13, 18 & trisomy 22 by FISH was likely chromosomally mosaic since only trisomy 22 was confirmed by aCGH in the single blastomere along with multiple monosomies. The corresponding embryo was diagnosed as trisomy 12, monosomy 14 by aCGH. Embryo 2 diagnosed as monosomy 18 and trisomy 21 by FISH was confirmed in both the single cell and whole embryo by aCGH. Moreover, aCGH identified additional aneusomies (monosomy 5, 8, 10, 12, & trisomy 9 in both single cell and corresponding embryo). Embryo 3 diagnosed as normal by FISH was confirmed to be normal for 24 chromosomes after aCGH. CONCLUSIONS: The theoretical benefits of using a 24-chromosome screen are clear in terms of comprehensive chromosomal coverage to identify aneuploidies responsible for implantation failure, viable trisomies and miscarriage. Currently, using this approach, we could confidently detect chromosomal aneuploidies after blastocyst biopsy or for follow-up analysis and whole embryo aneuploidy risk assessment. With optimized cell lysis, whole genome amplification and hybridisation efficiency we could provide a 24-chromosome screen for single blastomeres in a feasible time frame for clinical PGS.
small molecules
2026-03-30 | Methyldopa as a novel therapeutic option for paroxysmal sympathetic hyperactivity in pediatric patients: A case report
Background Paroxysmal sympathetic hyperactivity (PSH) is a clinical syndrome characterized by intermittent episodes of excessive sympathetic and motor activity, including tachycardia, hypertension, hyperthermia, tachypnea, excessive diaphoresis, and abnormal posturing. Clonidine, an α2-adrenergic agonist, is used as a treatment for PSH, demonstrating efficacy across multiple studies. However, market withdrawal and the lack of a generic alternative in Japan have prompted the need for other therapeutic options. Case presentations Case 1 was 2-year-old boy with trisomy 13 complicated by holoprosencephaly, severe intellectual disability, and mixed quadriplegia. His PSH had been well-controlled with clonidine, which was successfully replaced with methyldopa after discontinuation of the former. Case 2 was a 1-year-old boy diagnosed with early infantile epileptic encephalopathy caused by a KCNQ2 mutation. PSH symptoms and elevated creatine kinase levels were alleviated with gabapentin and methyldopa. Discussion and conclusion We present the first two pediatric cases of PSH successfully managed with methyldopa, another α2-adrenergic agonist, as an alternative to clonidine. Methyldopa may serve as a promising alternative treatment for pediatric patients with PSH, particularly in settings where clonidine is unavailable. Further studies are required to evaluate the efficacy, safety, and long-term outcomes of methyldopa in this population.
2025-04-01 | Unresolved Grief Resurfacing: managing delayed perinatal grief after subsequent birth
Introduction Delayed perinatal grief occurs when the grieving process for a lost baby is reactivated after the birth of a healthy child. This case presents a 39-year-old mother who, after losing her first baby at 36 weeks due to Patau syndrome, experienced delayed grief following the birth of a full-term baby two years later. Despite receiving one psychological consultation at the time of the loss, the lack of follow-up contributed to the reactivation of her grief postpartum, presenting with sadness and anxiety. Objectives - To describe the process of delayed perinatal grief in a mother who lost a baby due to Patau syndrome. - To evaluate the psychological impact of the lack of follow-up after the loss on the subsequent development of reactivated grief. - To propose therapeutic interventions for the management of mothers experiencing delayed perinatal grief. Methods We present the case of a 39-year-old mother who lost a baby at 36 weeks of gestation due to Patau syndrome. Following the loss, she received a single psychological consultation with no further follow-up. Two years later, she gave birth to a healthy baby at 40 weeks, and six weeks after delivery, she was referred to psychiatry due to symptoms of profound sadness and anxiety, consistent with delayed perinatal grief. The patient was evaluated by the psychiatry team and began treatment with psychological intervention and pharmacological management when necessary. Results The psychiatric intervention led to a gradual improvement in symptoms of sadness and anxiety. The patient responded favorably to psychological treatment, incorporating cognitive-behavioral therapy techniques to manage grief. However, feelings of sadness persisted on dates related to the previous loss. Ongoing emotional support was crucial for the recovery process. Conclusions Delayed perinatal grief can reactivate after the birth of a new child, especially in cases where the original loss was not adequately followed up. Proper psychological support is essential to help mothers process their grief and prevent long-term emotional complications. Disclosure of Interest None Declared
2025-02-09 | Supportive effect of corticosteroid on bone marrow recovery in FLT3/ITD positive acute myeloid leukemia with trisomy 13.
Trisomy 13 is a rare chromosomal abnormality mainly observed in patients with FAB M0, and is associated with increased FLT3 expression, characterized by aggressive and inferior outcomes. Herein, we describe a case of FLT3/ITD-positive acute myeloid leukemia with trisomy 13, whose neutropenia and thrombocytopenia were improved by corticosteroids with a decrease in blasts in the peripheral blood without chemotherapy. Only short-term chemotherapy could be administered because of the patient's poor general condition. In contrast, repeated administration of methylprednisolone pulse therapy followed by high-dose prednisolone was required to control the interstitial pneumonitis. Although appropriate chemotherapy, such as oral administration of FLT inhibitors, could not be administered, a dramatic decrease in blasts and an increase in both neutrophils and platelets were observed. The addition of corticosteroids to chemotherapy is associated with a better clinical course in patients with hyperleukocytic and pediatric acute myeloid leukemia. In the present patient, the peripheral WBC count was not high, the steroids allowed for the recovery of normal hematopoiesis with diminishing blasts. Although stem cell transplantation is necessary to improve overall survival for aggressive acute myeloid leukemia, intensive chemotherapy cannot often be administered in frail older patients. Lower dose of steroids might be able to effectively control acute myeloid leukemia without serious adverse effects, resulting in a better clinical course in frail older patients with acute myeloid leukemia.
2024-01-23 | Clinical and neurological aspects of endocrine disorders in Down syndrome in children
BACKGROUND: Down syndrome is a common genetic pathology in which multiple defects are observed, including endocrine disorders of varying severity. Hypothyroidism occupies a leading position among all hormonal disorders in such children. However, the significance of hypofunction of the thyroid gland in the development and progression of cerebral dysfunction in children with trisomy 21 has not been sufficiently studied.
AIM: Assessment of the impact of endocrine pathology in children with Down syndrome on the state of neurological functions.
MATERIALS AND METHODS: We examined 50 children aged 3–5 years with complete trisomy of chromosome 21. At the same time, the number of boys was 13 (32%), girls — 27 (68%). Children of the main group had verified endocrine disorders associated with Down syndrome. Children in the control group had a confirmed diagnosis of Down syndrome, but did not have endocrine pathology, and their number was 10 people — 8 girls (80%) and 2 boys (20). Everyone underwent speech therapy and neuropsychological examination. Children of the main and control groups, in addition to standard biochemical and general blood tests, underwent a detailed laboratory study with determination of T3, T4, TSH levels. An advisory examination and dynamic observation by a speech therapist for 6 months. All children were assessed by a neurologist according to generally accepted methods.
RESULTS: Data have been obtained indicating a fairly widespread prevalence of thyroid dysfunction among patients with Down syndrome. However, clinical symptoms may not be specific due to their similarity to the phenotypic manifestations of a genetic disease. Thus, patients with clinically significant hypothyroidism had more severe cognitive impairment. There was a significantly lower level of psycho-speech development in 95.3±3.1% of cases (p 0.001) according to the results of comprehensive neuropsychological and speech therapy examinations. In the group of children with severe hypothyroidism, significantly more severe disorders of mental functions were encountered. At the same time, as thyroxine was prescribed in age-appropriate dosages for 3 months, the child’s condition improved, mnestic functions and voluntary attention improved in 60% of patients in the main group. In 70% of cases, there was an improvement in the evacuation function of the gastrointestinal tract, in 65% there was a normalization of the humidity and temperature of the skin.
CONCLUSION: Timely diagnosis of thyroid gland dysfunction is an important preventive measure for genetic abnormalities associated with multiple comorbid pathologies, such as trisomy 21, Down syndrome. Timely correction of existing disorders can improve the quality of life of such children and their relatives and can contribute to their adequate socialization and adaptation in modern society.
2021-12-31 | Keratoconus in a child with partial trisomy 13.
Background: Clinical studies suggest the importance of genetic components in the etiology of keratoconus. However, the contributing genes and variants remain elusive. We present a case of bilateral keratoconus in a child with partial trisomy 13, with a trisomic region spanning loci that have been associated with keratoconus.Materials and Methods: This is a single, retrospective case report of a child with a molecular diagnosis of partial trisomy 13, who was diagnosed with bilateral keratoconus for which at the age of 11 years, she underwent successive epithelium-off corneal cross-linking (CXL) procedures in both eyes, followed by temporary central tarsorrhaphy under general anesthesia.Results: Patient's molecular diagnosis was 70 Megabase trisomic region 13q14.11q34. Pre CXL pachymetry was 426 μm and 496 μm, maximum K values were 52.28 D and 55.45 D in right and left eyes, respectively; at last follow up (12 months post-op) these were 494 μm and 509 μm for pachymetry and maximum K values 50.50 D and 52.43 D in the right and left eyes, respectively. No signs of progression were detected.Conclusion: To the best of our knowledge, this is the first case report to document bilateral keratoconus in a child with partial trisomy 13, in whom successful epithelium-off CXL was achieved with general anesthesia. We emphasize the importance of screening, early diagnosis, and therapy of this treatable but rare cause of decreased vision in partial trisomy 13 patients.
gene therapies
2026-08-15 | PATAU SYNDROME IN A NEONATE: A CYTOGENETICALLY CONFIRMED CASE REPORT
Background: Patau syndrome is a severe chromosomal disorder caused by trisomy of chromosome 13 and is associated with a characteristic but variable combination of central nervous system, craniofacial, ocular, cardiac, renal, and limb abnormalities.A one-day-old female neonate born at 38 completed weeks to a 46-year-old mother Case Presentation: was evaluated for multiple congenital anomalies.Birth weight was 2.37 kg and Apgar scores were 6 and 7 at 1 and 5 minutes.Examination showed cleft lip and palate, low-set ears, left microphthalmia, and polydactyly of the right hand, left hand and left foot.Echocardiography demonstrated a moderate perimembranous ventricular septal defect with leftto-right shunting, a small secundum atrial septal defect, and a patent ductus arteriosus, with preserved biventricular function.Neurosonography was suggestive of semilobar holoprosencephaly.Renal ultrasonography showed bilateral enlarged echogenic kidneys with multiple cortical cysts, consistent with congenital cystic renal dysplasia.Ophthalmological examination confirmed left microphthalmia with iris and chorioretinal coloboma.Conventional GTGbanded chromosome analysis demonstrated 47,XX,+13[20], establishing full, free trisomy 13 without a detectable normal cell line in peripheral blood.The coexistence of semilobar holoprosencephaly, orofacial clefting, Conclusion: microphthalmia with coloboma, polydactyly, congenital heart disease, and cystic renal dysplasia is strongly suggestive of trisomy 13.Karyotyping confirms the diagnosis, defines the cytogenetic subtype, and provides the basis for accurate prognostic discussion and reproductive genetic counseling.
2026-02-28 | Prognostic Factors and Pregnancy Outcomes in Fetuses Diagnosed with Cystic Hygroma during the First Trimester
AbstractAim: To evaluate the genetic, sonographic, and clinical characteristics of fetuses diagnosed with cystic hygroma in the first trimester and to identify prognostic factors influencing pregnancy outcomes.Material and Methods: This retrospective study included pregnancies diagnosed with fetal cystic hygroma during the first trimester between January 2023 and June 2025 at a tertiary center. Demographic data, ultrasound findings, and results of invasive genetic testing were analyzed. Cases were compared according to the presence or absence of chromosomal abnormalities to assess clinical and perinatal outcomes.Results: A total of 84 patients prenatally diagnosed as cystic hygroma were analyzed. Chromosomal abnormalities were identified in 33 cases (39.3%), including trisomy 21 (n=13), monosomy X (n=10), trisomy 18 (n=6), trisomy 13 (n=3), and mosaicism (n=1). Major fetal anomalies were detected in 24 cases (28.6%), most commonly cardiac defects (n=19, 22.6%). Hydrops fetalis was present in 25 fetuses (29.8%). Compared with the normal karyotype group, patients with chromosomal abnormalities had higher maternal age (p=0.037), greater NT thickness (p=0.008), and increased rates of hydrops (p=0.003), intrauterine fetal death (p=0.03), and pregnancy termination (p
2026-02-20 | Peculiar Phenotype of Linear Prepubertal Hidradenitis Suppurativa Associated With Trisomy 13: Report of Two Clinical Cases.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that typically affects intertriginous areas and is rarely associated with chromosomal abnormalities. This report describes two pediatric cases of HS-like lesions overlying phylloid pigmentary mosaicism, both associated with mosaic trisomy 13. The first case involves a 5-year-old girl with developmental anomalies and comedonal lesions localized to areas of pigmentary mosaicism, confirmed by skin biopsy showing 30% aneuploid cells with full trisomy 13. The second case is a 15-month-old girl who developed follicular lesions years later overlying a hypopigmented mosaic patch; genetic analysis of skin tissue revealed 50% aneuploid cells with partial trisomy 13. These cases support an emerging link between mosaic trisomy 13 and follicular occlusion disorders, including HS. The involvement of chromosome 13 genes, such as GJB2 (connexin 26), may play a role in the pathogenesis.
2025-07-02 | Antenatal Diagnosis of Disorders of Sex Development Associated with Trisomy 13: A Case Report
Introduction: Disorders of sex development (DSD) are rare congenital conditions characterized by atypical genital, gonadal, or chromosomal sex, with an incidence of 1/10,000 births. Antenatal ultrasound can detect ambiguous genitalia, prompting specialized evaluation. Case Presentation: A 30-year-old primigravida’s fetus was diagnosed with ambiguous genitalia (micropenis, hypospadias) at 22 weeks’ gestation via ultrasound. Trophoblast biopsy confirmed trisomy 13, and postnatal examination revealed additional dysmorphic features. Results: Multidisciplinary antenatal management included specialized ultrasound and genetic counseling, with postnatal confirmation of DSD and trisomy 13. Conclusion: This case highlights the importance of antenatal ultrasound in detecting DSD, the association with trisomy 13, and the need for comprehensive genetic and multidisciplinary evaluation.
2025-04-01 | A Newborn with Dysmorphic Features with Congenital Abnormality of Skin (Answers)
Winner of the Clinical Quiz Dr. Deepa John Thomas Assistant Professor, Department of Pediatrics Mount Zion Medical College, Kerala.Question 1: Identify the scalp lesions Answer: The scalp lesion described is aplasia cutis congenita (ACC). Aplasia cutis congenita is a rare congenital skin defect with an incidence of approximately 1–3 out of 10,000 births.[1] It is characterized by a focal or extensive absence of the epidermis, dermis, and subcutaneous tissue.[2] Nearly 70% of ACC lesions are solitary on the scalp. Question 2: Name the classification proposed for this skin condition Answer: Frieden classification is used for ACC. Nine described varieties of ACC have been documented according to the Frieden classification. Group 1: Scalp ACC without multiple anomalies Group 2: Scalp ACC with limb abnormalities Group 3: Scalp ACC with epidermal and organoid nevi Group 4: ACC overlying congenital malformations Group 5: ACC with associated fetus papyraceous placental infarct Group 6: ACC with epidermolysis bullosa Group 7: ACC localized to extremities without blistering Group 8: ACC due to specific teratogens Group 9: ACC associated with malformation syndromes. This case falls under Group 9 – ACC associated with malformation syndromes. Question 3: Identify the syndrome based on Images 1 and 2 and the features described in textImage 1: Scalp and facial anomalies at birth. (a) Midline scalp defects (~2 cm) extending into both parietal regions. (b) Cleft lip/palate, microcephaly, and hypertelorismImage 2: Limb abnormalities in the newborn. (a) Clenched hands with overlapping fingers. (b) Bilateral foot deformitiesAnswer: Based on the clinical features described including multiple scalp defects (ACC), characteristic facial dysmorphism (cleft lip, cleft palate, microcephaly, and hypertelorism), distinctive hand positioning (clenched hands with outer fingers overlapping inner fingers), foot deformities, cardiac involvement evidenced by pan-systolic murmur, and severe growth restriction (weight 1.18 kg at 35 weeks), this constellation of findings is suggestive of Trisomy 13 (Patau syndrome). Patau syndrome is one of the most severe forms of autosomal trisomies, having a karyotype of trisomy 13, and an incidence is 1 in 20,000 live births.[3] Question 4: Name one autosomal dominant and one autosomal recessive condition associated with this skin disorder Answer: The autosomal dominant (AD) and autosomal recessive (AR) conditions associated with ACC[4] are shown in Table 1. The most well-documented AD/AR condition with ACC is Adams–Oliver syndrome, which uniquely can be inherited in both AD and AR patterns depending on the specific gene involved.Table 1: Autosomal dominant and recessive conditions associated with aplasia cutis congenitaDeclaration of patient consent The authors certify that the legal guardian has given consent for images and other clinical information to be reported in the journal. The guardian understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.Comments by Dr. Ankita Patel (Section Editor) We hope you all enjoyed this stimulating quiz. Although the pictures may have been obvious, it was heartening to see good responses to the theoretical questions too. These unusual cases serve as valuable learning opportunities, enriching our understanding and expanding our clinical expertise. It was so nice to see such zealous response from all the corners of the country, and most of the responses were correct.
other
2026-06-27 | Neuroinflammatory Vulnerability Windows in Trisomy 21: A Theoretical Framework for Extended-Interval IL-13/TSLP Biologic Intervention During Fetal Neurodevelopment
This preprint proposes a theoretical framework identifying three neuroinflammatory vulnerability windows in trisomy 21 (Down syndrome) fetal neurodevelopment — early neurogenesis (weeks 8–16), synaptic pruning (weeks 20–28), and myelination onset (weeks 28–36) — during which extended-interval IL-13/TSLP-targeting biologics could theoretically modulate neuroinflammatory burden across the entire critical developmental period within two to three injections. The June 2026 acquisition of Apogee Therapeutics by AbbVie, centred on zumilokibart (an IL-13-specific monoclonal antibody with 3–6 month dosing intervals), and the concurrent development of APG273 (IL-13/TSLP dual blockade) provide the pharmacological basis for this hypothesis. The paper includes: a mechanistic evidence chain table graded by evidence strength; a comparative inflammatory target analysis (interferon vs IL-13/TSLP vs JAK inhibition vs DYRK1A); translational precedents from prenatal enzyme replacement therapy, antisense oligonucleotides, and monoclonal antibody use in pregnancy; expanded FcRn placental pharmacokinetics; a staged preclinical research roadmap (iPSC organoids → Ts65Dn/Dp16 mouse models → placental perfusion → non-human primates); and explicit falsifiability criteria. A companion computational simulation (Python, open-source) models maternal-fetal pharmacokinetics via a PBPK model and downstream neuroinflammatory response via an ODE system, producing 7 publication-quality figures including a Monte Carlo sensitivity analysis (n=100) and composite Neurodevelopmental Index. Simulation code is available on GitHub and attached to this Zenodo record. This paper explicitly affirms the full dignity and personhood of individuals with trisomy 21. The framework targets neuroinflammatory burden as a secondary modifiable factor — analogous to folate supplementation — and is not oriented toward prevention of Down syndrome births. This is a theoretical hypothesis framework intended to stimulate preclinical investigation and is not a clinical recommendation. Submitted to Medical Hypotheses.
2025-02-12 | Treatment efficacy for infantile epileptic spasms syndrome in children with trisomy 21
Background Infantile Epileptic Spasms Syndrome (IESS) is the most common epilepsy syndrome in children with trisomy 21. First-line standard treatments for IESS include adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin. Among children with trisomy 21 and IESS, treatment with ACTH or oral corticosteroids may yield higher response rates compared with vigabatrin. However, supporting data are largely from single-center, retrospective cohort studies. Methods Leveraging the multi-center, prospective National Infantile Spasms Consortium (NISC) database, we evaluated the efficacy of first-line (standard) treatments for IESS in children with trisomy 21. We assessed clinical spasms remission at two weeks, clinical spasms remission at three months, and improvement of EEG (resolution of hypsarrhythmia) three months after initiation of treatment. Results Thirty four of 644 (5.3%) children with IESS were diagnosed with trisomy 21. In all children with trisomy 21, epileptic spasms was their presenting seizure type. Twenty of 34 (59%) children were initially treated with ACTH, nine (26%) with oral corticosteroids, and five (15%) with vigabatrin. Baseline demographics did not vary among treatment groups. The overall clinical remission rate after two weeks of treatment was 53% including 13 of 20 (65%) receiving ACTH, three of nine (33%) receiving oral corticosteroids, and two of five (40%) receiving vigabatrin ( p = 0.24). The continued clinical response rate at three months was 32% including 8 of 20 (40%) receiving ACTH, two of nine (22%) receiving oral corticosteroids, and one of five (20%) receiving vigabatrin. Thirty of the 34 (88%) children presented with hypsarrhythmia (88%). EEG improvement at three months was better for children treated with ACTH (74%) or oral corticosteroids (83%) than vigabatrin (20%; p = 0.048). Adjustment for time from epileptic spasms onset to treatment did not alter results. Conclusions In our cohort, epileptic spasms were the first presenting seizure type in all children with trisomy 21. Among first-line standard treatment options, ACTH may have superior efficacy for clinical and electrographic outcomes for IESS in children with trisomy 21.
2022-07-11 | Severe recalcitrant hidradenitis suppurativa in a 2-year-old boy with partial trisomy 13.
We report the case of a 2-year-old boy with mosaic trisomy 13 and immunodeficiency who developed severe hidradenitis suppurativa beginning at the age of 18 months. Unresponsive to standard therapies, he exhibited a partial response to immunoglobulin replacement therapy.
2020-10-09 | Characteristics of the Central Nervous System Malformations Presented in Trisomy 13: A single-center Experience in Recognizing the Phenotype and Genotype
BACKGROUND: Patients who are diagnosed with trisomy 13 (Patau syndrome) are known to have a poor prognosis. It has been hypothesized that such poor outcomes are suspected to be attributed to their central nervous system (CNS)-malformations and cardiac-malformations. This study was conducted at Division of Neuropediatric, Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran – Dr. Hasan Sadikin Hospital, Bandung (2012–2018).
AIM: This study aimed to describe clinical characteristics and karyotype findings in patients who were diagnosed with Patau syndrome and treated at our center. Since Indonesia is still categorized as a lower middle-income country with limited resources, we expected that this study would provide a clinical reference on how a congenital disease with chromosomal abnormalities is confirmed.
CASE PRESENTATION: Our cases indicate that CNS malformations are likely to be the cause of indirect mortality of patients’ early period of life. The median survival in our study is 7 days, while the longest survival is 30 days. The major cause of death is apnea, which found in 4 of 5 diagnosed infants. One patient died of severe infection. In most cases, where CNS malformations were observed microcephaly with sloping forehead, Dandy–Walker syndrome, lobar or alobar holoprosencephaly and ventriculomegaly were identified, as well as neural tube defects (NTDs) were identified, such as spina bifida and meningoencephalocele. CNS malformations, such as holoprosencephaly, may be associated with episodes characterized by temporary cessation of spontaneous breathing (apnea) as direct cause of mortality.
CONCLUSION: We conclude that early treatment in Patau syndrome patient in our center should be focused on more life-threatening problem caused by CNS malformations than NTDs defects, such defects could be managed electively.
2017-05-07 | Acne conglobata in a long‐term survivor with trisomy 13, accompanied by selective IgM deficiency
Trisomy 13 (T13) is a congenital chromosomal disorder that is usually fatal within 2 years of birth, and only a few patients have been reported to reach adolescence. Here, we report a male long‐term survivor of T13, currently 15 years of age, with a several‐year history of extensive acne conglobata (AC) with abscesses on the face and neck. Methicillin‐resistant Staphylococcus aureus was consistently isolated from the pustular lesions. Serum IgM levels were extremely low at 10 mg/dl. There were no abnormalities in neutrophil and total B cell number, or in serum IgA and IgG levels. Increased CD8+ T cell counts and inversion of the CD4/CD8 ratio were observed repeatedly. The patient's clinical features and laboratory data support a diagnosis of selective IgM deficiency (SIgMD) with concurrent AC. Immunoglobulin replacement therapy elevated serum IgM levels to the normal range and reduced the severity of AC. We suggest that T13 may represent a syndromic disorder associated with multiple organ malformation and a risk of developing immunodeficiency involving SIgMD. Because pediatric SIgMD is rare and an immunological abnormality in T13 patients has not previously been reported, we describe the patient's clinical course.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.